Amaç: FIGO 2009 Evre 1B2 ve üzeri lokal ileri evre serviks kanserli hastalarda tedavi seçeneği olarak Radikal Histerektomi ile neoadjuvan kemoterapi sonrası Radikal Histerektominin genel ve hastalıksız sağkalıma etkisi araştırıldı. Gereç ve Yöntem: Çalışma Şubat 2007 – Ocak 2015 tarihleri arasında Başkent Üniversitesi Jinekolojik Onkoloji Bölümünde tedavi edilen 119 FİGO 2009 evre 1B2 ve üzeri lokal ileri serviks kanserli hastaları içermekte olup retrospektif olarak düzenlendi. Hastalar jinekolojik muayene ile klinik olarak evrelendirilip, görüntüleme tetkikleri ile değerlendirildikten sonra, tedavi planlarına göre 2 gruba ayrıldı. Primer olarak cerrahi yapılacak hastalara (grup1) Radikal histerektomi ve lenf nodu diseksiyonu yapıldı. Neoadjuvan kemoterapi uygulanan hastalarda ise (grup 2) 3 kür kemoterapi verildikten sonra radikal histerektomi ve lenf nodu diseksiyonu uygulandı. Çalışmada bu iki grup arasında genel ve hastalıksız sağkalım süreleri araştırıldı. Ayrıca genel ve hastalıksız sağkalımı etkileyen faktörler araştırıldı. Bulgular: Hastaların ortalama yaşı 56 (32-85) idi, ortalama takip süresi ise 35(1-100) aydı. 119 hastanın 36’sına neoadjuvan kemoterapi uygulanırken, 83 hasta primer cerrahi grubundaydı. 5 yıllık genel sağkalım neoadjuvan kemoterapi grubunda %51,7 (56,3 ay), primer cerrahi uygulanan grupta ise %73,5 (79,2 ay) olarak bulundu (p=0,03). Hastalıksız sağkalım ise neoadjuvan alan grupta %48,2 (49,2 ay) bulunurken bu oran primer cerrahi grubu için %61,4 (67,7 ay) olarak hesaplandı (p=0,17). Primer cerrahi yapılan grubunun genel sağ kalım hızı, neoadjuvan kemoterapi sonrası cerrahi uygulanan hastalardan anlamlı olarak yüksekti (p=0.036). Sonuç: Çalışmamızda servikal kanserli hastalarda uygulanan 2 farklı tedavi şekli karşılaştırılmış olup, primer olarak radikal histerektomi ve lenf nodu diseksiyonu yapılan hastalarda genel sağkalım hızının, neoadjuvan kemoterapi sonrası radikal histerektomi ile lenf nodu diseksiyonu uygulanan hastalardan istatiksel olarak daha iyi olduğu saptanmıştır. Neoadjuvan kemoterapi tedavisi lokal ileri evre serviks kanserli hastalarda standart bir tedavi şekli olmayıp çalışmamızda da genel ve hastalıksız sağkalıma etkisi olmadığı saptanmıştır. Neoadjuvan kemoterapinin lenf nodu tutulumuna ve tümör çapına etkisi olduğu bulunmuştur.

OBJECTIVES:Clinical findings support the critical importance of cervical screening and the management of abnormal cervical cytology results in female organ transplant recipients. We evaluated the incidence and prognosis of atypical cervical lesions in women who are kidney and liver transplant recipients at our organ transplant center. MATERIALS AND METHODS:We performed a retrospective cohort study of patients at Başkent University, Ankara, Türkiye, from March 2003 to January 2023. We included women who underwent at least 1 cervical cytology after kidney or liver transplant. The Bethesda System was used to classify cervical cytology results. We analyzed follow-up data by using descriptive statistics. RESULTS:Our study included 124 patients, with 98 (79%) being kidney transplant recipients and 26 (21%) being liver transplant recipients. The median age was 37.5 years. Atypical cervical cytology was detected in 34 patients (27.4%). The distribution of cervical cytology results was 90 with normal cytology (72.6%), 10 with atypical squamous cells of undetermined significance (8.1%), 23 with low-grade squamous intraepithelial lesion (18.5%), and 1 with high-grade squamous intraepithelial lesion (0.8%). Among these, 42 patients (33.9%) underwent colposcopy, revealing abnormal results in 10 patients (23.8%), including 1 (2.38%) with cervical cancer. CONCLUSIONS:The findings underline the significant prevalence of atypical cervical lesions among solid-organ recipient patients, highlighting the need for proactive cervical screening and management strategies in this high-risk population.

IntroductionThe aim of study was to compare the outcomes of stage III-IV ovarian cancer patients treated with NACT+İDS or PDS and to demonsrate the real life experience of a single centerMethodsThis retrospective case control study was carried out in Baskent University,Ankara,Turkey.Patients with high grade serous histology who diagnosed between 2007 and 2022 were evaluated .Patient ‘s characteristics and tumoral features like age,type of surgery,complications,OS,DFS were retrospectively documented.Results473 patienst included in PDS group and 143 patients included in NACT group.PDS group were slighly younger 57 y vs 59 y (p=006).Median follow up time was 44 months.PDS group were more subjected to extended surgery 46% vs 26% (p=0.001) ,however grade III-IV complications rates and RO resection rates were similar 6,8% vs 11,8% (p=0.18) and 78% vs 85% p=0.06 respectively . Median OS was 37 months (95% CI ;28,9–45,0) and 53 months (95% CI 48,2–57,2) for NACT and PDS group respectiveley ( p<0.00). Median DFS for NACT group was 12 months (95% CI ;10.2–13.7) and 15 months (95% CI 13.6–16.3) for PDS group ( p=0.002).İn the cox proportional hazard model NACT was associated with dimished DFS and OS (HR:1.3 ,95% CI:1.0–1.7; p=0.001) and (HR:1.6 ,95%CI:1.1–2.4; p=0.001 )Conclusion/Implicationsİn our retrospective cohort PDS seems to be more effective in the treatment of Stage III-IV ovarian cancer and patients who treated with PDS had better DFS and OS .

Introduction/Background In our clinical practice we began to plan paclitaxel rechallenge earlier (in thirdline) in patients with platine resistant recurrent high grade serous ovarian cancer (HG-SOC) and our aim is to evaluate the outcome of this approach with other prognostic factors. Methodology This retrospective study included 49 patients. Patient data including age, recurrence time, histopathological results, chemotherapy protocols, were obtained from the hospital database. Early paclitaxel rechallenge was defined as paclitaxel rechallenge in the thirdline after the secondline liposomal doxorubycin, late paclitaxel rechallenge was defined as treatment in further lines. Results The median age of the was 54 (range, 27–77). Median overall survival (OS) was 45 (range, 21–186) months. In survival analyses patients who underwent late rechallenge had worse overall survival (58.9 vs. 64.4 months, p:0.219) but this finding did not reach a statistical significance. In evaluation of challenges agent types patients who underwent single agent (only paclitaxel) had better OS when compared to two agents (paclitaxel + carboplatine); 67.6 vs 54.4 months (p:0.713) whereas this also did not reach a statistical significance. Conclusion Despite the later onset of approach and low number of patients the results of our study supports that early paclitaxel rechallenge may be promising in management of platine resistant recurrent high grade serous ovarian cancer. Also, single agent rechallenge may be a better option to avoid the chemotherapy related side effects with better overall survival results. Disclosures none

Introduction/Background Gemcitabine or liposomal doxorubicin are well-accepted chemotherapy modilities in management of recurrent high grade serous ovarian cancer (HG-SOC) with partial platinum response. In this study we aimed to evaluate the progression free intervals after the secondline gemcitabine or liposomal doxorubicin treatments in this group. Methodology This is a descriptive retrospective study including 67 patients with recurrent high grade serous ovarian cancer (HG-SOC) with partial platinum response. Partial response was defined as recurrence after 6 first-line therapies with platine derives in 6–12months. Patients who underwent gemcitabine + platine derives ± bevacizumab was defined as Group I and liposomal doxorubicin + platine derives ± bevacizumab as Group II. Results The median recurrence time of the whole group was 8 months. The mean initial recurrence times were 7.4±2.6 and 8.5±2.3 months for group I and II, respectively. The mean progression free survival time after in Group I and II were 13.6±6.1 and 13.7±19.7 months, (p:0.344), respectively. The estimated overall survival for groups were 59.0±7.2 months and 45.7±3.5 months but this was not statistically significant (p:0.135). Conclusion In our study, we found that progression free intervals after the secondline gemcitabine or liposomal doxorubicin treatments in patients recurrent high grade serous ovarian cancer (HG-SOC) with partial platinum response are similar. This finding may support use of liposomal doxorubicin with longer treatment intervals and less hospital admission for the patient. Disclosures none

ObjectiveThis study aimed to assess the long-term oncologic and obstetric outcomes of women with epithelial ovarian cancer who underwent fertility-sparing surgery. MethodsA total of 68 patients observed between March 2007 and July 2021 were included in this retrospective study. Unilateral salpingo-oophorectomy and uterine preservation with staging surgery were the main procedures for fertility-sparing surgery. Disease-free, overall survival, and obstetric outcomes were measured as primary outcomes. ResultsThe median age of the patients was 30.5 years. The median follow-up time was 60.5 months. Disease recurrence occurred in 15 (22.1%) of the patients. Five-year disease-free survival and overall survival (OS) percentages were 75.6% and 83.3%, respectively, for all stages. The FIGO (International Federation of Gynecology & Obstetrics) stage was the only significant factor that affected OS (P = 0.001). Twenty-three patients tried to conceive, and 15 (65.2%) patients became pregnant. Twelve (80%) pregnancies reached term and resulted in 15 live births. Chemotherapy administration and surgical intervention (cystectomy or unilateral salpingo-oophorectomy) showed no difference in pregnancy results (P = 0.806 and P = 0.066, respectively). ConclusionFertility preservation is safe for invasive epithelial ovarian cancer at early stages for women in the reproductive era. Disease recurrence and OS results are similar to standard treatment at early stages with decent obstetric outcomes.